On the first day of ATTD 2025, four cardiometabolic-related news items have been observed from Dexcom, Tandem Diabetes Care, Sequel Med Tech, and Welldoc. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: all 15 drug manufacturers agreed to participate in the second round CMS pricing negotiations (view press release) and Ypsomed and CamDiab launched mylife Loop on iOS systems (view press release).
A series of cardiometabolic-related news items has been observed from Bayer, Dexcom, Zealand Pharma, vTv Therapeutics, and Entera Bio/OPKO Health. Below, FENIX provides highlights and insight for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, Novo Nordisk, Senseonics, Esperion, and Fractyl Health. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Tandem Diabetes Care, Altimmune, Zevra Therapeutics, TIXiMED, MannKind, Silence Therapeutics, and Viatris. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Madrigal, NewAmsterdam Pharma, Lilly, and Senseonics. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Lilly, Tandem Diabetes Care, the Outsourcing Facilities Association, Lilly/Organovo, and Terns Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Viking Therapeutics/Pfizer, and Insulet. Below, FENIX provides highlights and insights for the respective news items.
Zealand FY Q4 ‘24 Earnings; Steve Pacelli Leaves Dexcom
Tandem initiated a trial evaluating the Tandem Freedom algorithm with its t:slim X2 pump in adults with T1DM (view CT.gov record). Existing Control-IQ technology users will use Control-IQ technology at home for a one-week run-in, then will use Tandem Freedom in a supervised hotel setting. For context, Tandem previously initiated the first feasibility trial for its Freedom algorithm in May 2024 (view CT.gov record). Below, FENIX provides highlights and insights into the trial.